• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

癌患者中 HE4 表达的预后价值：一项荟萃分析。

Prognostic values of HE4 expression in patients with cancer: a meta-analysis.

作者信息

Dai Cong, Zheng Yi, Li Yuanjie, Tian Tian, Wang Meng, Xu Peng, Deng Yujiao, Hao Qian, Wu Ying, Zhai Zhen, Dai Zhijun, Lyu Jun

机构信息

Clinical Research Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, People's Republic of China,

Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, People's Republic of China,

出版信息

Cancer Manag Res. 2018 Oct 10;10:4491-4500. doi: 10.2147/CMAR.S178345. eCollection 2018.

DOI:10.2147/CMAR.S178345
PMID:30349381
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6188164/
Abstract

BACKGROUND

To evaluate the prognostic impact of HE4 expression in patients with cancer.

MATERIALS AND METHODS

We searched the PubMed, Web of Science, Chinese National Knowledge Infrastructure and WangFang databases for publications concerning HE4 expression in patients with cancer. The correlation of HE4 expression level with overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) was analyzed.

RESULTS

In this meta-analysis, 29 studies, with a total of 4,235 patients, were included. Our results showed that HE4 expression was significantly associated with poorer OS (hazard ratio [HR] =2.15, 95% confidence interval [CI] =1.77-2.62, <0.001). Further subgroup analysis found that this correlation was not affected by race (White: HR =1.92, 95% CI =1.53-2.39, <0.001; Asian: HR =2.62, 95% CI =2.06-3.35, <0.001) or tumor types (endometrial cancer: HR =2.91, 95% CI =1.86-4.53, <0.001; ovarian cancer: HR =1.82, 95% CI =1.50-2.22, <0.001; lung cancer: HR =2.31, 95% CI =1.54-3.47, <0.001). Our meta-analysis showed that HE4 overexpression was significantly associated with DFS (HR =2.50, 95% CI =1.86-3.37, <0.001) and PFS (HR =1.27, 95% CI =1.11-1.45, =0.001).

CONCLUSION

These results suggest that expression of HE4 was associated with a worse prognosis in patients with cancer. HE4 is a potential novel prognostic factor in patients with cancer.

摘要

背景

评估癌胚抗原4（HE4）表达对癌症患者预后的影响。

材料与方法

我们检索了PubMed、科学网、中国知网和万方数据库，以查找有关癌症患者HE4表达的文献。分析了HE4表达水平与总生存期（OS）、无病生存期（DFS）和无进展生存期（PFS）的相关性。

结果

在这项荟萃分析中，纳入了29项研究，共4235例患者。我们的结果显示，HE4表达与较差的总生存期显著相关（风险比[HR]=2.15，95%置信区间[CI]=1.77-2.62，P<0.001）。进一步的亚组分析发现，这种相关性不受种族（白人：HR=1.92，95%CI=1.53-2.39，P<0.001；亚洲人：HR=2.62，95%CI=2.06-3.35，P<0.001）或肿瘤类型（子宫内膜癌：HR=2.91，95%CI=1.86-4.53，P<0.001；卵巢癌：HR=1.82，95%CI=1.50-2.22，P<0.001；肺癌：HR=2.31，95%CI=1.54-3.47，P<0.001）的影响。我们的荟萃分析显示，HE4过表达与无病生存期（HR=2.50，95%CI=1.86-3.37，P<0.001）和无进展生存期（HR=1.27，95%CI=1.11-1.45，P=0.001）显著相关。

结论

这些结果表明，HE4的表达与癌症患者较差的预后相关。HE4是癌症患者潜在的新型预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/c6d6716b622a/cmar-10-4491Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/8f958e3ff88f/cmar-10-4491Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/246b48d90f9a/cmar-10-4491Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/a8ede81205fb/cmar-10-4491Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/22ebdbc3564b/cmar-10-4491Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/6bed85e1c1b4/cmar-10-4491Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/c6d6716b622a/cmar-10-4491Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/8f958e3ff88f/cmar-10-4491Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/246b48d90f9a/cmar-10-4491Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/a8ede81205fb/cmar-10-4491Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/22ebdbc3564b/cmar-10-4491Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/6bed85e1c1b4/cmar-10-4491Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ad/6188164/c6d6716b622a/cmar-10-4491Fig6.jpg

相似文献

1
Prognostic values of HE4 expression in patients with cancer: a meta-analysis.癌患者中 HE4 表达的预后价值：一项荟萃分析。
Cancer Manag Res. 2018 Oct 10;10:4491-4500. doi: 10.2147/CMAR.S178345. eCollection 2018.
2
Prognostic value of HE4 in patients with ovarian cancer.HE4 在卵巢癌患者中的预后价值。
Clin Chem Lab Med. 2018 Jun 27;56(7):1026-1034. doi: 10.1515/cclm-2017-1176.
3
HE4 expression in lung cancer, a meta-analysis.肺癌中HE4的表达：一项荟萃分析
Clin Chim Acta. 2017 Jul;470:109-114. doi: 10.1016/j.cca.2017.05.007. Epub 2017 May 9.
4
Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta-analysis.人附睾蛋白 4 表达在子宫内膜癌患者中的预后价值：系统评价和荟萃分析。
J Obstet Gynaecol Res. 2022 Sep;48(9):2255-2269. doi: 10.1111/jog.15356. Epub 2022 Jul 17.
5
HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.人附睾蛋白 4 在原发性卵巢癌复发患者血浆中的表达与手术结果和总生存期相关。
Ann Surg Oncol. 2014 Mar;21(3):955-62. doi: 10.1245/s10434-013-3347-1. Epub 2013 Nov 12.
6
Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis.人附睾蛋白 4（HE4）在确定子宫内膜癌患者生存中的作用：一项荟萃分析。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820971660. doi: 10.1177/1533033820971660.
7
Prognostic Values of LAPTM4B-35 in Human Cancer: A Meta-analysis.LAPTM4B-35在人类癌症中的预后价值：一项荟萃分析。
J Cancer. 2018 Oct 21;9(23):4355-4362. doi: 10.7150/jca.26902. eCollection 2018.
8
Aldehyde dehydrogenase serves as a biomarker for worse survival profiles in ovarian cancer patients: an updated meta-analysis.醛脱氢酶可作为卵巢癌患者生存状况恶化的生物标志物：一项更新的荟萃分析。
BMC Womens Health. 2018 Dec 6;18(1):199. doi: 10.1186/s12905-018-0686-x.
9
Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.消化系统癌症患者中PD-L1表达的预后和预测价值：一项荟萃分析。
Onco Targets Ther. 2017 Jul 21;10:3625-3634. doi: 10.2147/OTT.S138044. eCollection 2017.
10
Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?一线化疗期间 HE4 水平测量能否预测卵巢癌患者的治疗反应？
PLoS One. 2018 Mar 27;13(3):e0194270. doi: 10.1371/journal.pone.0194270. eCollection 2018.

引用本文的文献

1
Protein Glycosylation as Biomarkers in Gynecologic Cancers.蛋白质糖基化作为妇科癌症的生物标志物
Diagnostics (Basel). 2022 Dec 15;12(12):3177. doi: 10.3390/diagnostics12123177.
2
Current and Emerging Prognostic Biomarkers in Endometrial Cancer.子宫内膜癌中当前及新出现的预后生物标志物
Front Oncol. 2022 Apr 22;12:890908. doi: 10.3389/fonc.2022.890908. eCollection 2022.
3
The Role of Human Epididymis Protein 4 in the Diagnosis and Prognosis of Diseases: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies.

本文引用的文献

1
HE4 expression in lung cancer, a meta-analysis.肺癌中HE4的表达：一项荟萃分析
Clin Chim Acta. 2017 Jul;470:109-114. doi: 10.1016/j.cca.2017.05.007. Epub 2017 May 9.
2
Development and validation of nomograms for predicting survival in patients with non-metastatic colorectal cancer.预测非转移性结直肠癌患者生存的列线图的开发与验证
Oncotarget. 2017 May 2;8(18):29857-29864. doi: 10.18632/oncotarget.16167.
3
Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.血清人附睾蛋白4与子宫内膜癌患者的预后因素及生存期相关。
人附睾蛋白4在疾病诊断和预后中的作用：观察性研究的系统评价和荟萃分析的伞状综述
Front Med (Lausanne). 2022 Mar 24;9:842002. doi: 10.3389/fmed.2022.842002. eCollection 2022.
4
HE4 as a Biomarker for Endometrial Cancer.人附睾蛋白4作为子宫内膜癌的生物标志物
Cancers (Basel). 2021 Sep 23;13(19):4764. doi: 10.3390/cancers13194764.
5
Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?HE4和CA125标志物的测定会影响子宫内膜癌患者的治疗吗？
Diagnostics (Basel). 2021 Mar 31;11(4):626. doi: 10.3390/diagnostics11040626.
6
Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer.血清 HE4 和 CA125 的早期清除预测上皮性卵巢癌对铂类药物的敏感性和预后。
J Ovarian Res. 2021 Jan 4;14(1):2. doi: 10.1186/s13048-020-00759-9.
7
Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis.人附睾蛋白 4（HE4）在确定子宫内膜癌患者生存中的作用：一项荟萃分析。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820971660. doi: 10.1177/1533033820971660.
8
Meta-analysis of the prognostic role of HE4 expression in cancer patients: clinical insights into interpretation of clinical outcomes.HE4表达在癌症患者中预后作用的Meta分析：对临床结果解读的临床见解
Cancer Manag Res. 2019 Feb 21;11:1791-1794. doi: 10.2147/CMAR.S198253. eCollection 2019.
Virchows Arch. 2017 Jun;470(6):655-664. doi: 10.1007/s00428-017-2115-1. Epub 2017 Apr 11.
4
Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.人附睾蛋白4在上皮性卵巢癌化疗耐药及预后中的作用
J Obstet Gynaecol Res. 2017 Jan;43(1):220-227. doi: 10.1111/jog.13181. Epub 2016 Nov 12.
5
HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer.人附睾蛋白4作为上皮性卵巢癌患者辅助化疗耐药性和生存的预测指标
APMIS. 2016 Dec;124(12):1038-1045. doi: 10.1111/apm.12625. Epub 2016 Nov 16.
6
Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma.胎盘型碱性磷酸酶在卵巢浆液性癌中的组织表达
Cancer Biomark. 2016;17(4):479-486. doi: 10.3233/CBM-160665.
7
Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.癌胚抗原和糖类抗原19-9对IV期结直肠癌患者R0切除术后的预后影响
J Surg Res. 2016 Oct;205(2):384-392. doi: 10.1016/j.jss.2016.06.078. Epub 2016 Jul 4.
8
Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance.着丝粒蛋白K（CENPK）在卵巢癌中的过表达与患者生存率低相关，并具有预测和预后相关性。
PeerJ. 2015 Nov 5;3:e1386. doi: 10.7717/peerj.1386. eCollection 2015.
9
Expression of HE4 in Endometrial Cancer and Its Clinical Significance.HE4在子宫内膜癌中的表达及其临床意义
Biomed Res Int. 2015;2015:437468. doi: 10.1155/2015/437468. Epub 2015 Oct 11.
10
Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma.膜联蛋白A2和人附睾蛋白4在子宫内膜癌中的表达及临床意义
J Exp Clin Cancer Res. 2015 Sep 11;34(1):96. doi: 10.1186/s13046-015-0208-8.